Legal & General Group
IMVT icon

Legal & General Group’s Immunovant IMVT Stock Holding History

Legal & General Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Sell
74,456
-18,258
-20% -$473K ﹤0.01% 1938
2025
Q4 		$2.36M Buy
92,714
+5,637
+6% +$126K ﹤0.01% 1903
2025
Q3 		$1.4M Buy
87,077
+9,781
+13% +$158K ﹤0.01% 2127
2025
Q2 		$1.24M Buy
77,296
+5,010
+7% +$75.8K ﹤0.01% 2170
2025
Q1 		$1.24M Buy
72,286
+13,296
+23% +$278K ﹤0.01% 2102
2024
Q4 		$1.46M Buy
58,990
+3,596
+6% +$102K ﹤0.01% 2112
2024
Q3 		$1.58M Buy
55,394
+1,410
+3% +$41.6K ﹤0.01% 2069
2024
Q2 		$1.43M Buy
53,984
+718
+1% +$20.4K ﹤0.01% 2074
2024
Q1 		$1.72M Sell
53,266
-222
-0.4% -$8.1K ﹤0.01% 1996
2023
Q4 		$2.25M Sell
53,488
-5,820
-10% -$214K ﹤0.01% 1889
2023
Q3 		$2.28M Buy
59,308
+8,530
+17% +$193K ﹤0.01% 1841
2023
Q2 		$963K Buy
50,778
+35,712
+237% +$666K ﹤0.01% 2237
2023
Q1 		$234K Buy
15,066
+867
+6% +$15K ﹤0.01% 2528
2022
Q4 		$252K Hold
14,199
– – ﹤0.01% 2523
2022
Q3 		$80K Sell
14,199
-14,860
-51% -$72.6K ﹤0.01% 2879
2022
Q2 		$113K Sell
29,059
-775
-3% -$3.35K ﹤0.01% 2824
2022
Q1 		$164K Buy
29,834
+141
+0.5% +$878 ﹤0.01% 2732
2021
Q4 		$253K Buy
29,693
+1,637
+6% +$13.5K ﹤0.01% 2619
2021
Q3 		$244K Buy
28,056
+7,071
+34% +$63.8K ﹤0.01% 2623
2021
Q2 		$222K Sell
20,985
-864
-4% -$12.1K ﹤0.01% 2508
2021
Q1 		$351K Buy
21,849
+16,288
+293% +$430K ﹤0.01% 2358
2020
Q4 		$258K Sell
5,561
-272
-5% -$12.6K ﹤0.01% 2370
2020
Q3 		$206K Buy
5,833
+1,685
+41% +$50.7K ﹤0.01% 2352
2020
Q2 		$101K Buy
+4,148
New +$88.9K ﹤0.01% 2527

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Legal & General Group's IMVT Position: Q1 2026 in Review

Legal & General Group reduced its Immunovant (IMVT) stake by 20% in Q1 2026, selling an estimated $473K and leaving 74,456 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

Legal & General Group first reported a position in IMVT in Q2 2020 and has held it in 24 quarters since. The position peaked at $2.36M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Legal & General Group held 74,456 shares of Immunovant worth $1.85M as of Q1 2026.
  • Legal & General Group sold 18,258 Immunovant shares in Q1 2026, an estimated $473K.
  • Immunovant made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1938 holding.
  • Legal & General Group first reported a position in Immunovant in Q2 2020 and has held it in 24 quarters since.
  • Legal & General Group's Immunovant position peaked at $2.36M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.